scholarly journals Inhibitor of DNA-binding family regulates the prognosis of ovarian cancer

2021 ◽  
Vol 17 (15) ◽  
pp. 1889-1906
Author(s):  
Quan Zhou ◽  
Ye-Dong Mei ◽  
Huai-Jie Yang ◽  
Ya-Ling Tao
Keyword(s):  
Ovarian Cancer ◽  
Dna Binding ◽  
Prognostic Value ◽  
High Risk Group ◽  
Kaplan Meier ◽  
Mutational Status ◽  
Inhibitor Of Dna Binding ◽  
Pathological Stages ◽  
Tp53 Mutational Status

Aim: The mechanistic role of inhibitor of DNA binding or differentiation (ID) family in ovarian cancer (OC) has remained unclear. Materials & methods: We used the Oncomine, GEPIA, Kaplan–Meier Plotter, cBioPortal, SurvExpress, PROGgene V2, TIMER, and FunRich to evaluate the prognostic value of IDs in patients with OC. Results: the mRNA transcripts of all IDs were markedly downregulated in OC compared with normal tissue. The prognostic value of IDs was also explored within the subtypes, pathological stages, clinical stages and TP53 mutational status. The group with low-risk IDs showed relatively good overall survival (OS) compared with the high-risk group. Conclusion: ID1/3/4 may be exploited as promising prognostic biomarkers and therapeutic targets in OC patients.

scholarly journals The Inhibitor of DNA Binding Family Regulates the Prognosis of Ovarian Cancer

2020 ◽  
Author(s):  
Quan Zhou ◽  
Ye-dong Mei Mei ◽  
Yang Huai-jie ◽  
Tao Ya-ling
Keyword(s):  
Ovarian Cancer ◽  
Dna Binding ◽  
Prognostic Value ◽  
Enrichment Analysis ◽  
High Risk Group ◽  
Aberrant Expression ◽  
Kaplan Meier ◽  
Mutational Status ◽  
Cancer Aggressiveness ◽  
Inhibitor Of Dna Binding

Abstract Background: The inhibitor of DNA binding or differentiation (ID) protein family contributes to the carcinogenesis and progression of various cancers. However, its mechanistic role in tumor initiation and progression of ovarian cancer (OC) has remained unclear. Methods: We used the Oncomine, GEPIA, Kaplan-Meier plotter, cBioPortal, SurvExpress, PROGgene V2 server, TIMERdatabase, and FunRich to evaluate the expression and predictive prognostic value of individual IDs members’ mRNA in patients with OC. Results: Our results revealed that the mRNA transcripts of all ID family members were markedly downregulated in OC compared to normal tissue. Aberrant expression of ID 1/3/4correlated with cancer aggressiveness and clinical in OC patients. The prognostic value of ID members was also explored within the subtypes, pathological stages, clinical stages, and TP53 mutational status. The group with a low risk IDs showed a relatively good overall survival (OS) in comparison to the high-risk group. In contrast, the expression level of IDs was significantly associated with the levels of infiltrating B cells and macrophages. Finally, enrichment analysis showed that ID co-expressed genes were involved in ID-, c-MYC, TNF-, and Wnt signaling pathways. Conclusion: These results indicate that ID1/3/4 may be exploited as promising prognostic biomarkers and therapeutic targets in OC patients.

scholarly journals The role of phosphoprotein phosphatases catalytic subunit genes in pancreatic cancer

2021 ◽  
Vol 41 (1) ◽  
Author(s):  
Junjie Hang ◽  
Steven Yuk-Fai Lau ◽  
Ruohan Yin ◽  
Lina Zhu ◽  
Siyuan Zhou ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Prognostic Value ◽  
Chi Square ◽  
Catalytic Subunits ◽  
Beneficial Effects ◽  
Phosphoprotein Phosphatases ◽  
Kaplan Meier ◽  
Chi Square Test ◽  
Independent Cohort

Abstract Compelling evidence suggests that phosphoprotein phosphatases (PPPs) are involved in a large spectrum of physiological and pathological processes, but little is known about their roles in pancreatic cancer. We investigated the expression level, prognostic value, and potential function of PPPs with data from Oncomine, GEPIA, THPA, and TCGA databases and an independent cohort of patients with pancreatic cancer. Among all the PPP catalytic subunits (PPPcs), the transcription levels of PPP1CA, PPP1CB, PPP3CA, PPP3CB, and PPP4C were higher in pancreatic cancer than in normal pancreas (P<0.01, fold change > 2). Kaplan–Meier analysis showed that high transcription levels of PPP1CA, PPP1CB, PPP2CA, PPP2CB, PPP3CA, and PPP4C correlated with poorer survival. In contrast, patients with high levels of PPP3CB, PPP3CC, PPP5C, PPP6C, and PPEF2 had much better prognoses. Data from THPA and patients with pancreatic cancer enrolled in our hospital also confirmed the prognostic value of PPP1CA, PPP1CB, PPP2CA, PPP2CB, PPP3CA, PPP3CB, and PPP6C at the protein level. In addition, the Pearson Chi-square test showed that PPP3CB level was significantly correlated with T and N stages. GO and KEGG analyses showed that the genes and pathways related to the pathogenesis and progression of pancreatic cancer were greatly affected by alterations in PPPcs. Results of the present study suggest that PPP1CA, PPP1CB, PPP2CA, PPP2CB, and PPP3CA have deleterious effects but PPP3CB, PPP5C, and PPP6C have beneficial effects on pancreatic cancer.

scholarly journals Increased expression of TET3 predicts unfavorable prognosis in patients with ovarian cancer-a bioinformatics integrative analysis

2019 ◽  
Vol 12 (1) ◽  
Author(s):  
Tiefeng Cao ◽  
Wenwei Pan ◽  
Xiaoli Sun ◽  
Huimin Shen
Keyword(s):  
Ovarian Cancer ◽  
Dna Demethylation ◽  
Integrative Analysis ◽  
Gynecological Malignancy ◽  
Kaplan Meier ◽  
The Family ◽  
Elevated Expression ◽  
Integrative Study ◽  
Cancer Tissues

Abstract Ovarian carcinoma is a lethal gynecological malignancy. Women with ovarian cancer (OC) are highly recurrent and typically diagnosed at late stage. Ten-eleven translocation protein 3 (TET3) belongs to the family of ten-eleven translocations (TETs) which induce DNA demethylation and gene regulation in epigenetic level by converting 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC). Previous studies indicated that TET3 is overexpressed in ovarian cancer tissues. However, the clinic-pathological functions and prognostic values of TET3 remain unclear. Here we performed an integrative study to identify the role of TET3 by bioinformatics analysis. The TET3 expression in ovarian cancer was assessed with Oncomine database, and validated with TCGA and GTEx database. The correlation of TET3 gene alteration and clinic-pathological functions was addressed by integrative analysis of GEO datasets. Then we showed mainly TET3 gain and diploid but less deletion in ovarian cancer by copy number alteration (CNA) or mutation analysis with cBioPortal. Furthermore, by using Kaplan-Meier plotter (K-M plotter), we evaluated that high TET3 level was associated with poor survival in ovarian cancer patients, which was validated with analysis by PrognoScan database and gene differential analyses with TCGA and GTEx. This is the first study demonstrated that elevated expression of TET3 is associated with poor clinic-pathological functions, poor prognosis, wherein TET3, which presents epigenetic changes or methylation changes, might be served as a diagnostic marker or therapeutic target for ovarian cancer.

scholarly journals Bromine domain protein 4 is an important marker for prognosis of ovarian cancer and tumor immune infiltration

2021 ◽  
Author(s):  
Chujia Chen ◽  
Zhiyong Yang ◽  
Qiuchan Zhao ◽  
Bangming Xu ◽  
Donglin Cao
Keyword(s):  
Ovarian Cancer ◽  
Immune Cell ◽  
Expression Level ◽  
Immune Markers ◽  
Immune Infiltration ◽  
Normal Tissues ◽  
Kaplan Meier ◽  
Domain Protein ◽  
Kaplan Meier Plotter

Abstract Background Ovarian cancer (OC) is one of the most common malignant gynecological tumors, but its pathogenesis is unclear. Bromine domain protein 4 (BRD4) is involved in the malignant transformation of cells, as well as the invasion and metastasis of tumor cells. The biological role of BRD4 in ovarian cancer is yet to be determined. Methods The differential expression of BRD4 in OC and corresponding normal tissues was evaluated by exploring the Tumor Immune Assessment Resources (TIMER) and the Oncomine database. The correlation between the expression level of BRD4 and the prognosis of OC patients was evaluated using the Kaplan-Meier Plotter database. Using TIMER, we further studied the correlation between BRD4 and tumor immune cell infiltration. Results The expression of BRD4 was significantly higher in patients with OC, and high BRD4 expression was closely related to low overall survival rate. The BRD4 expression was associated with the levels of immune markers of macrophages, dendritic cells, neutrophils, and various effector T cells. Taken together, these findings show that BRD4 expression is significantly related to immune infiltration in OC and suggest that BRD4 might play an important role in the immune evasion of OC cells. Conclusion The expression level of BRD4 in OC tissues is significantly upregulated, and its high expression is significantly associated with poor prognosis of patients and is closely related to tumor immune infiltration. These results suggest that BRD4 can be used as a prognostic marker and a marker of immune infiltration in OC.

scholarly journals Role of Baseline Albumin-Bilirubin Grade on Predict Overall Survival Among Sorafenib-Treated Patients With Hepatocellular Carcinoma in Vietnam

2019 ◽  
Vol 26 (1) ◽  
pp. 107327481986526 ◽  
Author(s):  
Thi Thu Huong Nguyen ◽  
Van Hieu Nguyen ◽  
Van Hung Nguyen ◽  
Thanh Long Nguyen ◽  
Van Quang Le
Keyword(s):  
Hepatocellular Carcinoma ◽  
Prognostic Value ◽  
Independent Predictor ◽  
Survival Outcome ◽  
Risk Of Death ◽  
Kaplan Meier ◽  
Liver Functions ◽  
Tertiary Hospitals ◽  
Grade 3

Introduction: Albumin-bilirubin (ALBI) grade has been recently used in evaluation of liver function and prognosis of patients with hepatocellular carcinoma (HCC). However, in Vietnam, the utility of ALBI grade in clinical setting has not been adequately investigated. Methods: This is a retrospective study of 110 patients with HCC treated with sorafenib from January 2010 to November 2018 at 2 tertiary hospitals in Vietnam. Prognostic value of ALBI grade was evaluated by Kaplan-Meier survival analysis and Cox proportional regression model. Results: Results showed that the majority of ALBI grade 1 were Child-Pugh level A (97.5%); ALBI grade 2 was seen in all Child-Pugh score groups of 5, 6, 7, ≥8, whereas ALBI grade 3 was mostly reported in Child-Pugh score ≥8 group (83.3%). Compared with ALBI grade 3, ALBI grade 1 reduced 66.4% risk of death (hazards ratio [HR] = 0.336, 95% confidence interval [CI]: 0.115-0.981; P = .046). Compared with ALBI grade 3, ALBI grade 2 reduced 67.3% risk of death (HR = 0.327, 95% CI: 0.122-0.875; P = .026). Albumin-bilirubin grade was an independent predictor of survival outcome. Conclusion: Baseline ALBI grade is a simple and objective approach in assessing liver functions of patients with HCC. Baseline ALBI grade is an independent predictor of survival in patients treated with sorafenib.

PROREPAIR-A: Clinical and molecular characterization study of prostate cancer (PC) patients with and without previously known germline BRCA1/2 mutations.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 5511-5511
Author(s):  
Rebeca Lozano ◽  
Elena Castro ◽  
Isabel Aragon ◽  
Heather Thorne ◽  
Fernando López-Campos ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Prognostic Value ◽  
Cox Regression ◽  
Castration Resistance ◽  
Free Survival ◽  
Kaplan Meier ◽  
Characterization Study ◽  
Control Study ◽  
Cause Specific Survival

5511 Background: Germline BRCA1/2 (g BRCA1/2) mutations are associated with poor clinical outcomes in PC. Previous studies showed that g BRCA2 carriers present more CNV in several genes associated with more aggressive disease. These aberrations may explain the poor clinical outcomes of these patients, but larger studies are needed to confirm these findings. Methods: PROREPAIR-A is a multicenter case-control study in which g BRCA2 carriers with available diagnostic timor-tissue were matched 1:2 by Gleason and stage at diagnosis (M0 vs M1) with known non-carriers (NC). A minimum of 120 controls-60 cases were required to prove a 5yr Cause Specific Survival (CSS)-rate of 85% vs 60%. The primary endpoint was to confirm the independent prognostic value of g BRCA2 in PC CSS. In addition, we explored the prognostic role of g BRCA1 and somatic events in BRCA2, RB1, MYC, PTEN and TMPRSS2-ERG by FISH. Χ2, Kaplan-Meier, log-rank and cox-regression models were carried out to identify associations with baseline characteristics and outcomes: Metastases Free Survival (MFS), Time to Castration-Resistance (TTCR) and CSS. Results: A total of 80:160 matched cases-controls were initially included, but tumor tissue and clinical data were only available in 73 g BRCA2 and 127 NC. 14 g BRCA1 were also included. At diagnosis, g BRCA2 were younger (median 62.6 vs 64.5, p = 0.02) and had cT3-4 disease more often than NC (31.5% vs 9.4%, p < 0.01), but no other significant differences were found. Somatic BRCA2-RB1 codeletion (40.8% vs 11.8%, p < 0.01) and MYC amplification (51.4% vs 22.8%, p < 0.01) were more frequent in g BRCA2 compared to NC, but no significant differences in PTEN and TMPRSS2-ERG were observed. g BRCA2 mutations as well as somatic BRCA2-RB1 codel and MYC amplif were significantly associated with shorter CSS, MFS and TTCR (Table). MVA model confirmed the independent prognostic value of g BRCA2 (HR 1.94, p = 0.03), BRCA2-RB1 codel (HR 3.16, p < 0.01), MYC amplif (HR 2.36, p < 0.01), Gleason ≥8 (p < 0.01) and M1 at diagnosis (p < 0.01) for CSS. Conclusions: PROREPAIR-A confirmed the independent prognostic value of g BRCA2 for CSS. Somatic BRCA2, RB1 and MYC aberrations were more frequent in g BRCA2 carriers. Those alterations are associated with shorter CSS, MFS and TTCR, and may contribute to poor clinical outcomes in g BRCA2 and NC. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document